本研究旨在评估恶性腹膜间皮瘤 (MPeM) 的人口统计学、临床病理学和预后特征，以及罕见和异质性 MPeM 人群的治疗选择。由于研究人群的异质性，该研究根据治疗、随访期和预后特征将其分为两组，第一组包括接受细胞减灭术（CRS）和腹腔热灌注化疗的患者。 (HIPEC)，第二组包括无法进行根治性手术的转移性疾病患者，这些患者的诊断程序和治疗方法是根据病历确定的，年龄超过 18 岁的患者无论是否患有石棉。研究中不包括分化良好的乳头状和多囊性间皮瘤组织学类型。该研究评估了来自五个中心的 118 名患者。分析两组的生存时间、预后和治疗反应。研究表明，CRS-HIPEC 与更长的总生存期 (OS) 和无进展生存期 (PFS) 相关。围手术期治疗在该人群的亚组分析中进行了评估，并显示可提供生存益处。接受化疗的患者（转移性患者和无法手术的患者以及无法实现完全细胞减灭术的患者）的预后比手术组更差。研究表明，由于任何原因不适合接受手术的患者，预期寿命显着下降。根据经验丰富的中心数据，CRS-HIPEC是公认的有效、经济、安全的治疗选择，具有更好的OS和PFS ，以及与文献中相似的低发病率和死亡率。此外，对于转移性患者、因医学原因无法手术的患者以及无法实现完全或接近完全细胞减灭术的患者，铂-培美曲塞组合仍然是一种有效且可接受的治疗选择。© 2024。作者。

This study aimed to evaluate the demographic," clinicopathologic, and prognostic characteristics of malignant peritoneal mesothelioma (MPeM), as well as the treatment options for the rare and heterogeneous MPeM population.A retrospective multi-center observational cohort study was conducted to evaluate patients with MPeM. Due to the heterogeneity of the study population, the study divided them into two main groups in terms of treatments, follow-up periods, and prognostic features. The first group comprised the patients who underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and the second group included the patients with metastatic disease for whom curative intent surgery was not possible. The patients' diagnostic procedures and treatments were identified from medical records. Patients older than 18 years old were included in the study regardless of asbestos exposure. Well-differentiated papillary and multicystic mesothelioma histologic types were not included in the study.The study evaluated 118 patients from five centers. Survival times, prognosis, and treatment responses were analyzed in both groups. The study showed that CRS-HIPEC was associated with longer overall survival (OS) and progression-free survival (PFS). Perioperative therapy was evaluated in subgroup analyses of this population and shown to provide survival benefits. The patients treated with chemotherapy (metastatic and medically inoperable patients and those for whom complete cytoreduction was not achievable) had a poorer prognosis than the surgery group. The study showed that life expectancy decreased significantly for the patients not suitable to undergo surgery for any reason.According to data from experienced centers, CRS-HIPEC is a treatment option recognized as effective, cost-effective, and safe, with better OS and PFS , as well as low morbidity and mortality rates similar to those in the literature. In addition, the platinum-pemetrexed combination continues to be an effective and acceptable treatment option for metastatic patients, those who are medically inoperable, and those for whom complete or near-complete cytoreduction is not achievable.© 2024. The Author(s).